These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 27089546)
1. Endocrine control of benign prostatic hyperplasia. La Vignera S; Condorelli RA; Russo GI; Morgia G; Calogero AE Andrology; 2016 May; 4(3):404-11. PubMed ID: 27089546 [TBL] [Abstract][Full Text] [Related]
2. Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia. Tong Y; Zhou RY Mediators Inflamm; 2020; 2020():7958316. PubMed ID: 33192175 [TBL] [Abstract][Full Text] [Related]
3. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Nicholson TM; Ricke WA Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560 [TBL] [Abstract][Full Text] [Related]
4. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Sakamoto S; Yokoyama M; Zhang X; Prakash K; Nagao K; Hatanaka T; Getzenberg RH; Kakehi Y Endocrinology; 2004 Jun; 145(6):2929-40. PubMed ID: 14988385 [TBL] [Abstract][Full Text] [Related]
5. Testosterone and Benign Prostatic Hyperplasia. Rastrelli G; Vignozzi L; Corona G; Maggi M Sex Med Rev; 2019 Apr; 7(2):259-271. PubMed ID: 30803920 [TBL] [Abstract][Full Text] [Related]
6. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Fibbi B; Penna G; Morelli A; Adorini L; Maggi M Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330 [TBL] [Abstract][Full Text] [Related]
8. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. Vignozzi L; Cellai I; Santi R; Lombardelli L; Morelli A; Comeglio P; Filippi S; Logiodice F; Carini M; Nesi G; Gacci M; Piccinni MP; Adorini L; Maggi M J Endocrinol; 2012 Jul; 214(1):31-43. PubMed ID: 22562653 [TBL] [Abstract][Full Text] [Related]
9. Role of the stromal microenvironment in carcinogenesis of the prostate. Cunha GR; Hayward SW; Wang YZ; Ricke WA Int J Cancer; 2003 Oct; 107(1):1-10. PubMed ID: 12925950 [TBL] [Abstract][Full Text] [Related]
10. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606 [TBL] [Abstract][Full Text] [Related]
11. Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia. Popovics P; Awadallah WN; Kohrt SE; Case TC; Miller NL; Ricke EA; Huang W; Ramirez-Solano M; Liu Q; Vezina CM; Matusik RJ; Ricke WA; Grabowska MM Prostate; 2020 Jul; 80(10):731-741. PubMed ID: 32356572 [TBL] [Abstract][Full Text] [Related]
12. Clinical and experimental studies of benign prostatic hyperplasia. Coffey DS; Walsh PC Urol Clin North Am; 1990 Aug; 17(3):461-75. PubMed ID: 1695775 [TBL] [Abstract][Full Text] [Related]
13. Role of stroma in carcinogenesis of the prostate. Cunha GR; Hayward SW; Wang YZ Differentiation; 2002 Dec; 70(9-10):473-85. PubMed ID: 12492490 [TBL] [Abstract][Full Text] [Related]